Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients

Oral Oncology

Volumn 50, Issue 5, 2014, Pages 498-505

  Reddy, B K M ^a   Lokesh, V ^a   Vidyasagar, M S ^b   Shenoy, K ^c   Babu, K G ^a   Shenoy, A ^a   Naveen, T ^a   Joseph, Bindhu ^a   Bonanthaya, R ^a   Nanjundappa, ^a   Bapsy, P P ^a   Loknatha, ^a   Shetty, Jayarama ^c   Prasad, Krishna ^c   Tanvir Pasha, C R ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

^b KASTURBA HOSPITAL   (India)

^c KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Chemoradiation; Epidermal growth factor receptor; Head and neck cancer; Humanized monoclonal antibody; Nimotuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NIMOTUZUMAB;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS;

EID: 84899092174     PISSN: 13688375     EISSN: 18790593     Source Type: Journal    
DOI: 10.1016/j.oraloncology.2013.11.008     Document Type: Article

References (36)

1. C.W. Reuter, M.A. Morgan, and A. Eckardt Targeting EGF-receptor- signalling in squamous cell carcinomas of the head and neck Br J Cancer 96 3 2007 408 416
2. Department of Biostatistics and Cancer Registry. Kidwai Memorial Institute of Oncology; 2011.
3. J.B. Vermorken, and P. Specenier Optimal treatment for recurrent/metastatic head and neck cancer Ann Oncol 21 Suppl 7 2010 vii252 vii261
4. D.C. Oksuz, R.J. Prestwich, B. Carey, S. Wilson, M.S. Senocak, and A. Choudhury et al. Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy Radiat Oncol 6 2011 54
5. D.G. Pfister, Y.B. Su, D.H. Kraus, S.L. Wolden, E. Lis, and T.B. Aliff et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm J Clin Oncol 24 7 2006 1072 1078
6. B.E. Brockstein Management of recurrent head and neck cancer: recent progress and future directions Drugs 71 12 2011 1551 1559
7. T. Tanvetyanon, T. Padhya, J. McCaffrey, W. Zhu, D. Boulware, and R. Deconti et al. Prognostic factors for survival after salvage reirradiation of head and neck cancer J Clin Oncol 27 12 2009 1983 1991
8. A.J. Ekstrand, C.D. James, W.K. Cavenee, B. Seliger, R.F. Pettersson, and V.P. Collins Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo Cancer Res 51 8 1991 2164 2172
9. S.E. Little, D.A. Bax, M. Rodriguez-Pinilla, R. Natrajan, B. Messahel, and K. Pritchard-Jones et al. Multifaceted dysregulation of the epidermal growth factor receptor pathway in clear cell sarcoma of the kidney Clin Cancer Res 13 15 Pt 1 2007 4360 4364
10. P. Stanton, S. Richards, J. Reeves, M. Nikolic, K. Edington, and L. Clark et al. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts Br J Cancer 70 3 1994 427 433
11. D.M. Shin, J.Y. Ro, W.K. Hong, and W.N. Hittelman Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis Cancer Res 54 12 1994 3153 3159
12. C. Bianco, G. Tortora, R. Bianco, R. Caputo, B.M. Veneziani, and V. Damiano et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa) Clin Cancer Res 8 10 2002 3250 3258
13. Z. Ai, J. Wang, Y. Wang, L. Lu, J. Tong, and Y. Teng Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway Cancer 116 15 2010 3603 3613
14. S. Nowsheen, J.A. Bonner, A.F. Lobuglio, H. Trummell, A.C. Whitley, and M.C. Dobelbower et al. Cetuximab augments cytotoxicity with poly (adp-ribose) polymerase inhibition in head and neck cancer PLoS One 6 8 2011 e24148
15. J.A. Bonner, P.M. Harari, J. Giralt, N. Azarnia, D.M. Shin, and R.B. Cohen et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck N Engl J Med 354 6 2006 567 578
16. M.G. Kris, R.B. Natale, R.S. Herbst, T.J. Lynch Jr, D. Prager, and C.P. Belani et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 16 2003 2149 2158
17. R. Rosell, T. Moran, C. Queralt, R. Porta, F. Cardenal, and C. Camps et al. Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 361 10 2009 958 967
18. A.C. Pickhard, J. Margraf, A. Knopf, T. Stark, G. Piontek, and C. Beck et al. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways BMC Cancer 11 2011 388
19. C. Mateo, E. Moreno, K. Amour, J. Lombardero, W. Harris, and R. Perez Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity Immunotechnology 3 1 1997 71 81
20. M.O. Rodriguez, T.C. Rivero, R. del Castillo Bahi, C.R. Muchuli, M.A. Bilbao, and E.N. Vinageras et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck Cancer Biol Ther 9 5 2010 343 349
21. M.E. Arteaga, N. Ledon, A. Casaco, B. Pardo, M. García, and M. Boleda et al. Systemic and skin toxicity in Cercopithecus aethiops sabaeus monkeys treated during 26 weeks with a high intravenous dose of the anti- epidermal growth factor receptor monoclonal antibody Nimotuzumab Cancer Biol Ther 6 9 2007 1390 1395
22. F. Rojo, E. Gracias, N. Villena, T. Cruz, J.M. Corominas, and I. Corradino et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study Clin Cancer Res 16 8 2010 2474 2482
23. G.P. Browman, C. Cripps, D.I. Hodson, L. Eapen, J. Sathya, and M.N. Levine Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer J Clin Oncol 12 12 1994 2648 2653
24. J.B. Vermorken, E. Remenar, C. van Herpen, T. Gorlia, R. Mesia, and M. Degardin et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer N Engl J Med 357 17 2007 1695 1704
25. R.K. Ngan, H.H. Yiu, W.H. Lau, S. Yau, F.Y. Cheung, and T.M. Chan et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study Ann Oncol 13 8 2002 1252 1258
26. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 2000 205 216
27. J.A. Bonner, P.M. Harari, J. Giralt, R.B. Cohen, C.U. Jones, and R.K. Sur et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival Lancet Oncol 11 1 2010 21 28
28. R. Pazdur Endpoints for assessing drug activity in clinical trials Oncologist 13 Suppl 2 2008 19 21
29. C. Basavaraj, P. Sierra, J. Shivu, R. Melarkode, E. Montero, and P. Nair Nimotuzumab with chemoradiation confers a survival advantage in treatment-naive head and neck tumors over expressing EGFR Cancer Biol Ther 10 7 2010 673 681
30. G. Snedecar, and W.G. Cochrane Statistical methods 6th ed. 1968 Oxford and IBH Publishing Company New Delhi
31. H.Q. Wang, T. Quan, T. He, T.F. Franke, J.J. Voorhees, and G.J. Fisher Epidermal growth factor receptor-dependent, NF-kappaB-independent activation of the phosphatidylinositol 3-kinase/Akt pathway inhibits ultraviolet irradiation-induced caspases-3, -8, and -9 in human keratinocytes J Biol Chem 278 46 2003 45737 45745
32. H.F. Li, J.S. Kim, and T. Waldman Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells Radiat Oncol 4 2009 43
33. M. Nagane, A. Levitzki, A. Gazit, W.K. Cavenee, and H.J. Huang Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases Proc Natl Acad Sci USA 95 10 1998 5724 5729
34. X. Wang, K.D. McCullough, T.F. Franke, and N.J. Holbrook Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival J Biol Chem 275 19 2000 14624 14631
35. A.L. Agero, S.W. Dusza, C. Benvenuto-Andrade, K.J. Busam, P. Myskowski, and A.C. Halpern Dermatologic side effects associated with the epidermal growth factor receptor inhibitors J Am Acad Dermatol 55 4 2006 657 670
36. G. Garrido, I.A. Tikhomirov, A. Rabasa, E. Yang, E. Gracia, and N. Iznaga et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile Cancer Biol Ther 11 4 2011 373 382